From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy.

Abstract

Narcolepsy, a rare disease with a prevalence of 0.05% in the general population, affects an estimated 140,000 patients in the United States. Patients have been able to lead fuller personal and professional lives since the Food and Drug Administration approved sodium oxybate (Xyrem) in 2002 for treatment of cataplexy in patients with narcolepsy. Previously, gamma-hydroxybutyrate (GHB), the active ingredient of sodium oxybate, had been a substance of abuse, most notoriously as a date-rape drug. Public Law 106-172, the date-rape prohibition act enacted in 2000, was modified to allow the drug to be legally administered for medical purposes. Because of the apprehension regarding the risk of possible drug diversion after the approval of sodium oxybate and concerns about safety, the Xyrem Risk Management Program was created. This program has been successful in satisfying the needs of patients and physicians while ensuring responsible distribution of the drug.

• Authors: David E Fuller, Carl S Hornfeldt
• Journal: Pharmacotherapy (Pharmacotherapy) Vol. 23 Issue 9 Pg. 1205-9 (Sep 2003) ISSN: 0277-0008 [Print] United States
• PMID: 14524654 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Illicit Drugs
• Sodium Oxybate

Topics

• Administration, Oral
• Cataplexy (drug therapy, physiopathology)
• Drug Approval
• Humans
• Illicit Drugs
• Orphan Drug Production
• Product Surveillance, Postmarketing (methods)
• Risk Management (organization & administration)
• Sodium Oxybate (administration & dosage, adverse effects, therapeutic use)
• United States
• United States Food and Drug Administration